Hoon Sik Choi et al., 2021-08-24: Choi et al. compare six benzimidazoles in triple-negative breast cancer cells and allograft mice, reporting that mebendazole reduces tumour volume and lung metastasis without liver or kidney toxicity.
Moreover, oral treatment with 10 mg/kg of MBZ daily for 2 consecutive weeks on a schedule of 5-days-on and 2-days-off did not affect body weight and did not cause liver or kidney toxicity in treated mice, but showed a significant decrease in tumor volume and lung metastasis.
Hoon Sik Choi et al., 2021-08-24: Choi et al. compare six benzimidazoles in triple-negative breast cancer cells and allograft mice, reporting that mebendazole reduces tumour volume and lung metastasis without liver or kidney toxicity. Study type: TNBC and radiotherapy-resistant TNBC cell lines plus allograft mice. N: six mice per group in the safety arm. Country: Korea (Gyeongsang National University). Dose: 10 mg/kg by oral gavage, daily, 5 days on/2 days off for 2 weeks. Funder: National Research Foundation of Korea (NRF-2017R1D1A1B03033907; NRF-2020R1I1A3057533). Declared conflicts: 'The authors declare no conflict of interest.' Comparator: five other benzimidazoles (albendazole, flubendazole, fenbendazole and others) and vehicle. Study type: animal.
